Impact of trisomy 12, del13q, del17p, and del11q on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic Bcells in chronic lymphocytic leukemiaHow to cite this article: Quijano S, López A, Rasillo A, Sayagués JM, Barrena S, Sánchez ML, Teodosio C, Giraldo P, Giralt M, Pérez MC, Romero M, Perdiguer L, Orfao A. Impact of trisomy 12, del13q, del17p, and del11q on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic BCells in chronic lymphocytic leukemia. Cytometry Part B 2008; 74B: 139–149.

Bcell chronic lymphocytic leukemia BCLL is a welldefined clinical entity with heterogeneous molecular and cytogenetic features. Here, we analyze the impact of trisomy 12, del13q, del17p, and del11q as determined by interphase fluorescence in situ hybridization analysis of purified neoplastic BCLL cells on their immunophenotype, DNA ploidy status and proliferative rate.Overall, 111 of 180 62 BCLL cases studied displayed one 50 or more 12 genetic abnormalities, del13q 35 being more frequently detected than trisomy 12 23 followed by del11q 9 and del17p 8. Trisomy 12 was associated with a higher frequency of DNA aneuploidy, stronger expression of CD19, CD20, CD22, CD24, CD27, CD79b, CD38, and sIg and lower reactivity for CD43 with respect to cytogenetically nonaltered cases. In turn, cases with del13q displayed greater reactivity for CD20, FMC7, CD27, CD22, CD5, and bcl2, while del11q was associated with brighter expression of CD38, FMC7, CD25, and sIg. Hierarchical clustering analysis of the immunophenotype of BCLL cases with cytogenetic abnormalities allowed the identification of three different groups of patients with increasing frequencies of trisomy 12, del11q, and del13q. Remarkably, none of the cytogenetic abnormalities analyzed except coexistence of 13q and 17phad a clear impact on the proliferative index of BCLL cells. © 2007 Clinical Cytometry Society